Clarivate Epidemiology’s coverage of acute heart failure (AHF) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France…
Clarivate Epidemiology’s coverage of chronic heart failure (CHF) comprises epidemiological estimates of key patient populations across the major mature pharmaceutical markets (the United States,…
Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key acute heart failure patient populations, covering 171 countries and…
Biomarker-driven prescribing is paramount in key oncology indications. The use of biomarkers is entrenched in non-small-cell lung cancer (NSCLC), breast cancer, and colorectal cancer. Biomarker-…
Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key chronic heart failure patient populations, covering 171 countries…
Clarivate Epidemiology’s coverage of heart failure (HF) comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the diagnosed event rates of AHF…
Clarivate Epidemiology’s coverage of heart failure (HF) comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the diagnosed event rates of AHF…